Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LeMaitre Vascular, Inc. - Common Stock (NQ:LMAT)

97.49 +0.42 (+0.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LeMaitre Vascular, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Sidoti Events, LLC's Virtual June Small-Cap Conference
Via ACCESSWIRE
Is This Healthcare Stock a Buy for Dividend Growth Investors?
This medical device maker has crushed the S&P 500 index in the past 10 years. 
Via The Motley Fool
Why Shares of LeMaitre Vascular Are Up Wednesday
LeMaitre announced first-quarter earnings and guidance numbers. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
 
Via Benzinga
Recap: LeMaitre Vascular Q1 Earnings
 
Via Benzinga
Buy This Under-the-Radar Stock for Dividend Growth
This specialty medical device maker treats its shareholders well. 
Via The Motley Fool
Is This Small-Cap Dividend Stock a Buy?
LeMaitre Vascular isn't well-known to investors. But vascular surgeons do know the company well. 
Via The Motley Fool
The Best Dividend Achievers
The Dividend Achievers show a minimum of 10 consecutive years with a dividend increase. Here are some of the top Dividend Achievers from 5 different sectors. 
Via Talk Markets
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time for a dive into the latest stock market happenings with the biggest pre-market stock movers worth watching on Friday! 
Via InvestorPlace
Income Investors: These 2 Stocks Have Quadrupled Their Dividend Payouts Over the Past 10 Years
These two stocks have generated massive dividend growth for shareholders in the last decade. 
Via The Motley Fool
Is This Underfollowed Dividend Stock a Buy?
The medical device maker flies under the radar of most investors. 
Via The Motley Fool
Weibo, XPeng, Li Auto And Other Big Losers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 800 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
6 Overlooked Dividend Stocks For Your Buy List
A discussion about 6 dividend stocks that no one talks about. 
Via Talk Markets
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
Stocks Boast Midday Gains On Road To Big Weekly Weekly Wins
Wall Street is brushing off a dismal earnings report from Amazon.com, and opting to favor unsurprising inflation and steady consumer spending data. 
Via Talk Markets
Why Edwards Lifesciences Shares Are Trading Lower By Around 17%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) surged 179% to $3.6301. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022
Upgrades 
Via Benzinga
High Growth Potential Small-Cap Dividend Stock Ideas [Podcast]
Looking for growth in the dividend world? Small caps are in for a rollercoaster ride, but can bring a lot of growth to your portfolio. Often overlooked, these companies still tend to outperform large... 
Via Talk Markets
Recap: LeMaitre Vascular Q4 Earnings
LeMaitre Vascular (NASDAQ:LMAT) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Why You Should Consider Buying This Little-Known Medical Devices Stock
LeMaitre Vascular is a small-cap medical devices maker with the potential to continue growing rapidly in the years ahead. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers MiNK Therapeutics (NASDAQ:INKT) shares rose 16.88% to $16.96 during Friday's regular session. Vocera Communications (NYSE:VCRA) shares increased by 12.13% to $... 
Via Benzinga
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
Lemaitre Vascular Inc (LMAT) Q3 2021 Earnings Call Transcript
LMAT earnings call for the period ending August 31, 2021. 
Via The Motley Fool
Topics Earnings
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Bellerophon Therapeutics (NASDAQ: 
Via Benzinga
Recap: LeMaitre Vascular Q3 Earnings
LeMaitre Vascular (NASDAQ:LMAT) reported its Q3 earnings results on Thursday, October 28, 2021 at 04:05 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.